Pharmavigilance/Safety

The largest neutral healthcare conference in Europe for life sciences professionals to address the hottest challenges. As the knowledge and innovation hub uniting science, healthcare, patients and regulatory professionals, DIA Europe commits to transforming insights into action by bridging the gap between critical policy discussions and real-world expertise. 

The Gene Therapy for Muscular Disorders Summit took place in April this year, and is the field’s only industry-focused event specifically designed to help gene therapy developers successfully target the muscle. With a disease-agnostic agenda, but highlighting novel research in Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease and X-Linked Myotubular Myopathy (XLMTM), the expert industry speakers from the likes of Solid Biosciences, Sarepta Therapeutics, Astellas Gene Therapies and Pfizer spent 4-days discussing the fields hottest topics from navigating toxicity to state-of-the-art muscular targeting.

ASCPT Annual Meeting attendees include clinical pharmacologists, pharmacists, and others whose primary interest is to promote and advance the science of human pharmacology and therapeutics.

The World Drug Safety Congress Americas will bring together 1000+ top leaders and stakeholders in biopharma to discuss the key challenges they are facing in pharmacovigilance and device safety. Explore strategies in data management & signal detection, showcase how AI & machine learning have improved PV processes, discuss the challenges creating a PV strategy for advanced therapies, and collaborate on medical device safety strategies.

Engage in scientific discussions on the latest tools and technologies for accelerated NK-based cellular immunotherapy development. Benefit from exclusive insights from global influencers in NK based cell therapy, addressing strategies for safety, quality control and off-target activity assessment, with the goal to fast track to clinic.

A two-day event with dedicated streams on the latest tools and technologies for advanced understanding of cell-based products, including optimised cell line development, strategies to overcome bottlenecks and improved efficacy and safety of cell and gene therapies to ensure clinical and commercial product success.

The World Drug Safety Congress Europe is empowering patients, physicians, pharma, biotech and consumers to make the best drug safety decisions. We’ll bring together 600+ key thought leaders to explore these challenges within pharmacovigilance. Explore the use of big data and AI in pharmacovigilance, examine benefit-risk management strategies and patient-centric approaches; discuss how you can tackle the challenges of social media and drug safety legislation globally.

The Scientific Program features a diverse range of scientific sessions organized into two concurrent themed tracks covering issues such as Novel In Vitro and In Silico Assays to Predict Human Safety, In Vivo and Ex vivo Case Studies For Safety, Debate on the “Value” of Primary Tissue and In Vivo Studies and are disease Models Relevant in Safety Pharmacology, Macro Molecules Science: Antibodies, Oligo, and Peptides, Translation Beyond FIH Exposure Response Models, Macro Molecules Science: Gene therapy, Cell Therapy, mRNA and PROTAC, Derisking and Risk Mitigation Strategies, Clinical Cardiology, and much more! This will ensure attendees can stay abreast of new content and developments in key areas of interest. 

With more than 6,500 toxicologists from all over the world expected to attend, opportunities for networking and finding new collaborators are abundant—from the Scientific Sessions and other daytime events through the evening receptions. Research organizations, government agencies, drug developers, regulatory authorities, academic institutions, laboratory and medical suppliers, or consultants are encouraged to exhibit at ToxExpo.

RAPS Convergence is the largest and most well-recognized annual gathering of regulatory professionals, scientists, and innovators in the world. Convergence brings together representatives from industry, global regulatory bodies, and research, academic and clinical organizations that are directly involved in managing the regulatory process and aligning science, regulation, and business strategy.